Verheul Henk M W, Pinedo Herbert M
University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Nat Rev Cancer. 2007 Jun;7(6):475-85. doi: 10.1038/nrc2152.
Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with cancer. The toxicity profiles of these inhibitors reflect the disturbance of growth factor signalling pathways that are important for maintaining homeostasis. Experiences with angiogenesis inhibitors in clinical trials indicate that short-term toxicities are mostly manageable. However, these agents will also be given in prolonged treatment strategies, so we need to anticipate possible long-term toxicities. In addition, understanding the molecular mechanisms involved in the toxicity of angiogenesis inhibition should allow more specific and more potent inhibitors to be developed.
与最初的预期相反，血管生成抑制剂可在癌症患者中引发毒性。这些抑制剂的毒性特征反映了对维持体内平衡至关重要的生长因子信号通路的紊乱。临床试验中使用血管生成抑制剂的经验表明，短期毒性大多是可控的。然而，这些药物也将用于长期治疗策略中，因此我们需要预测可能的长期毒性。此外，了解血管生成抑制毒性所涉及的分子机制应有助于开发更具特异性和更强效的抑制剂。
